Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EBITDA: 2011-2025

Historic EBITDA for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $51.0 million.

  • Adma Biologics' EBITDA rose 28.69% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $167.0 million, marking a year-over-year increase of 45.36%. This contributed to the annual value of $139.0 million for FY2024, which is 542.49% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' EBITDA is $51.0 million, which was up 19.19% from $42.8 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' EBITDA ranged from a high of $51.0 million in Q3 2025 and a low of -$15.6 million during Q2 2021.
  • In the last 3 years, Adma Biologics' EBITDA had a median value of $34.9 million in 2025 and averaged $26.3 million.
  • Its EBITDA has fluctuated over the past 5 years, first declined by 4.61% in 2021, then skyrocketed by 8,387.74% in 2024.
  • Adma Biologics' EBITDA (Quarterly) stood at -$13.2 million in 2021, then spiked by 54.07% to -$6.1 million in 2022, then spiked by 334.93% to $14.2 million in 2023, then surged by 169.25% to $38.3 million in 2024, then grew by 28.69% to $51.0 million in 2025.
  • Its EBITDA stands at $51.0 million for Q3 2025, versus $42.8 million for Q2 2025 and $34.9 million for Q1 2025.